Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

722 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort.
Neau D, Trimoulet P, Pereira E, Lafon ME, Gervais A, Ragnaud JM, Dupon M, Ecobichon JL, Chêne G, Raffi F; ANRS CO8 APROCO-COPILOTE Study Group. Neau D, et al. Among authors: raffi f. J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):227-9. doi: 10.1097/QAI.0b013e31816d9cc3. J Acquir Immune Defic Syndr. 2008. PMID: 18520685 No abstract available.
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.
Le Moing V, Chêne G, Leport C, Lewden C, Duran S, Garré M, Masquelier B, Dupon M, Raffi F; Antiprotéases Cohorte (APROCO) Study Group. Le Moing V, et al. Among authors: raffi f. Clin Infect Dis. 2002 Jan 15;34(2):239-47. doi: 10.1086/324354. Epub 2001 Dec 4. Clin Infect Dis. 2002. PMID: 11740714
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.
Savès M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chêne G; Antiprotéases Cohorte (APROCO) Study Group. Savès M, et al. Among authors: raffi f. Clin Infect Dis. 2002 May 15;34(10):1396-405. doi: 10.1086/339866. Epub 2002 Apr 22. Clin Infect Dis. 2002. PMID: 11981737
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
Lewden C, Raffi F, Cuzin L, Cailleton V, Vildé JL, Chêne G, Allavena C, Salamon R, Leport C. Lewden C, et al. Among authors: raffi f. J Infect Dis. 2002 Sep 1;186(5):710-4. doi: 10.1086/342047. Epub 2002 Jul 29. J Infect Dis. 2002. PMID: 12195361 Clinical Trial.
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
Masquelier B, Droz C, Dary M, Perronne C, Ferré V, Spire B, Descamps D, Raffi F, Brun-Vézinet F, Chêne G; APROCO/COPILOTE Study Group. Masquelier B, et al. Among authors: raffi f. Antimicrob Agents Chemother. 2003 Nov;47(11):3623-6. doi: 10.1128/AAC.47.11.3623-3626.2003. Antimicrob Agents Chemother. 2003. PMID: 14576131 Free PMC article. Clinical Trial.
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group. Le Moing V, et al. Among authors: raffi f. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9. doi: 10.1097/00126334-200312150-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14657760
722 results